2-(2.6-DICHLOROPHENYLAMINO)-2-IMIDAZOLINE HYDROCHLORIDE (ST 155 OR CATAPRESAN) AS A PROPHYLACTIC REMEDY AGAINST MIGRAINE

Abstract

Twenty‐six migraine patients were included in a double blind study of the migraine‐reducing effect of 2‐(2.6‐dichlorophenylamino)‐2‐imidazoline hydrochloride (ST 155 or Catapresan). Sixteen of 26 patients (i.e. 62 per cent) experienced a reduction in headache indices when medicated with 75 μg of ST 155 daily (p < 0.025). The side effects of ST 155 in this dosage were trifling: a few patients complained of slight thirst, dryness of the mouth, or slight lethargy during the initial phase of drug therapy.